Up a level |
Vogel, Arndt, Frenette, Catherine, Sung, Max, Daniele, Bruno, Baron, Ari, Chan, Stephen L, Blanc, Jean Frederic, Tamai, Toshiyuki, Ren, Min, Lim, Howard J et al (show 3 more authors)
(2021)
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.
LIVER CANCER, 10 (5).
pp. 510-521.
Kudo, Masatoshi ORCID: 0000-0002-4102-3474, Finn, Richard S ORCID: 0000-0003-2494-2126, Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii ORCID: 0000-0002-9152-6512, Vogel, Arndt ORCID: 0000-0003-0560-5538, Tovoli, Francesco ORCID: 0000-0002-8350-1155, Ueshima, Kazuomi ORCID: 0000-0002-7577-5789, Aikata, Hiroshi ORCID: 0000-0002-3409-2156 et al (show 10 more authors)
(2023)
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Journal of hepatology, 78 (1).
pp. 133-141.
Verset, Gontran, Borbath, Ivan, Karwal, Mark, Verslype, Chris, Van Vlierberghe, Hans, Kardosh, Adel, Zagonel, Vittorina, Stal, Per, Sarker, Debashis, Palmer, Daniel H ORCID: 0000-0002-7147-5703 et al (show 16 more authors)
(2022)
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
CLINICAL CANCER RESEARCH, 28 (12).
pp. 2547-2554.
Kudo, Masatoshi, Finn, Richard S, Edeline, Julien, Cattan, Stephane, Ogasawara, Sadahisa, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt et al (show 11 more authors)
(2022)
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
EUROPEAN JOURNAL OF CANCER, 167.
pp. 1-12.